Paul Chapman MD

Dr. Paul B. Chapman is currently Clinical Director of Melanoma and Attending Physician in the Department of Medicine at Memorial Sloan Kettering Cancer Center. He is also Professor of Medicine at Weill Cornell Medical College. He graduated from Cornell University Medical College, completed internship and residency training in Internal Medicine at the University of Chicago, and did his Medical Oncology fellowship at Memorial Sloan Kettering. He is board-certified in Internal Medicine and Medical Oncology and has spent his career working on melanoma.

He was in the laboratory of Alan Houghton and focused initially on immunotherapy of melanoma. He conducted clinical and laboratory research on the question of immune recognition of melanoma. This included developing a vaccine against GD3 ganglioside and conducting pre-clinical and clinical studies that culminated in an international, randomized phase III trial. Recently his clinical research has also focused on inhibitors of kinases that are mutated or otherwise critical for melanoma growth. He was the Principal Investigator for the phase III randomized trial that led to FDA approval of vemurafenib, the first BRAF inhibitors for melanoma.